ArticleJournal of clinical medicine2026

Targeting the Epithelial Alarmin Pathway with Tezepelumab in Highly Comorbid, Biologic-Experienced Severe Asthma: 52-Week Real-World Outcomes.

Ruperto González-Pérez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.